The convergence of religion and modern medicine has catalyzed growing interest in halal pharmaceuticals—medicinal products formulated in accordance with Islamic law (Shariah), free from prohibited substances such as alcohol, porcine derivatives, and impure materials. As the global Muslim population approaches 2.2 billion by 2030, demand for halal-certified pharmaceuticals is rising, fueled by religious awareness, chronic disease burden, and consumer preferences for ethical and transparent healthcare products. This paper explores the multifaceted ecosystem of halal pharmaceuticals, examining market dynamics, consumer behavior, and industry responses. It highlights the challenges of ingredient sourcing, halal certification, and regulatory inconsistencies across regions. Central to the development of halal-compliant therapeutics is education—spanning curriculum development for medical and pharmacy students, continuing professional development for healthcare providers, and public health initiatives aimed at raising awareness. Ethical considerations rooted in Islamic bioethics—such as the sanctity of life, autonomy, and the permissibility of treatment under necessity (darurah)—are essential in shaping a culturally sensitive and morally sound pharmaceutical landscape. Furthermore, interdisciplinary collaboration among scholars, clinicians, regulators, and the pharmaceutical industry is critical for addressing complex bioethical dilemmas in drug development and therapeutic decision-making. The paper concludes by emphasizing the need for enhanced investment in research and education, curricular reform, and global cooperation to advance halal pharmaceutical science and practice. By integrating ethical, scientific, and cultural principles, halal pharmaceuticals offer a transformative model for inclusive and patient-centered healthcare.